Eton Pharmaceutcials, Inc. Common Stock ETON

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

• GlobeNewswire Inc. 27 ago

  Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

  Eton Pharmaceuticals announced record Q2 2026 revenue with product sales of $37.6 million, representing 99% year-over-year growth. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with EBITDA of $14.1 million. Additionally, Eton expanded its infantile hemangioma franchise by acquiring U.S. rights to ASN-001, a late-stage product candidate targeting moderate infantile hemangiomas, complementing its existing HEMANGEOL product.

  

• GlobeNewswire Inc. 5 ago

  Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

  Eton Pharmaceuticals has licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals for treating moderate infantile hemangiomas. Phase II/III trial results showed 56% elimination rates at week 24 with twice-daily dosing versus 15% for placebo. The company plans to submit an NDA in H2 2027 with potential approval and launch in 2028, targeting an estimated 20,000-30,000 patients annually and positioning ASN-001 as a complementary product to its existing HEMANGEOL therapy.

  

• GlobeNewswire Inc. 3 ago

  Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

  Eton Pharmaceuticals announced it will report second quarter 2026 financial results on August 13, 2026, with a conference call at 4:30 p.m. ET. The company also announced a Prior Approval Supplement submission to expand KHINDIVI's indication for a larger pediatric patient population and expanded its rare disease portfolio through commercialization rights to IMPAVIDO®.